Securin

securin-separase conserved

securin phosphorylation sites2

Network picture

Complete network

Securin, also known as pituitary tumor-transforming gene 1 (PTTG1) protein, is a crucial protein involved in the regulation of the cell cycle. It plays a significant role in ensuring proper chromosome segregation during cell division, particularly during the mitotic phase. The regulation of securin is vital for maintaining genomic stability and preventing aneuploidy, a condition that can lead to cancer and other diseases.

Function

Securin inhibits a protease known as separase, which is essential for the separation of sister chromatids during anaphase of mitosis. By inhibiting separase, securin prevents premature chromatid separation, ensuring that chromosomes are evenly distributed to the daughter cells. The controlled degradation of securin, mediated by the Anaphase Promoting Complex (APC), triggers the activation of separase, thereby allowing chromosome segregation to proceed.

Regulation

The regulation of securin is tightly controlled and involves several key mechanisms. The Anaphase Promoting Complex (APC), in conjunction with its co-activator Cdc20, targets securin for ubiquitination and subsequent degradation by the proteasome. This degradation is essential for the timely progression of mitosis. Additionally, securin levels are regulated through transcriptional control, with its expression being cell cycle-dependent.

Clinical Significance

Abnormalities in securin expression or function can lead to improper chromosome segregation, resulting in genomic instability, a hallmark of cancer. Overexpression of securin has been observed in various tumors, suggesting its role in tumorigenesis. As such, securin is considered a potential target for cancer therapy, with research focused on understanding its regulation and function in cancer cells.

Research

Ongoing research aims to elucidate the detailed mechanisms of securin regulation and its interaction with separase, as well as its role in tumorigenesis. Studies are also exploring the potential of targeting securin as a therapeutic strategy in cancer treatment.